Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
| Autor: | Samar Abohamad, Kadambari Vijaykumar, Mohanad M. Elfishawi, Hamdy M. Ahmed, Mohamed Tharwat Hegazy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
safety
medicine.medical_specialty patient satisfaction Medicine (miscellaneous) Safety margin Review Food and drug administration 03 medical and health sciences 0302 clinical medicine Patient satisfaction auto-injector Internal medicine self-injection medicine adherence 030212 general & internal medicine Pharmacology Toxicology and Pharmaceutics (miscellaneous) Prefilled Syringe 030203 arthritis & rheumatology business.industry Health Policy Self injection Belimumab Auto-Injector subcutaneous belimumab business Social Sciences (miscellaneous) medicine.drug |
| Zdroj: | Patient preference and adherence |
| ISSN: | 1177-889X |
| DOI: | 10.2147/ppa.s147163 |
| Popis: | Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies' production. Recently, the US Food and Drug Administration approved subcutaneous belimumab for patients who have received training on using it. Subcutaneous belimumab can be administered using either a prefilled syringe or an auto-injector device. Weekly subcutaneous belimumab seems to be as effective as monthly intravenous belimumab with a similar safety margin. In this article, we reviewed the literature on subcutaneous belimumab focusing on safety and patients' experiences and satisfaction. Overall, subcutaneous belimumab appears to be preferred over intravenous belimumab for a number of reasons. However, more studies are still required to prove these findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |